TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02453204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting
Study: NCT02813694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: antibacterial agent
Study: NCT02453204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Study: NCT02725723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therm-AppTM TH, thermographic camera

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural injection
Study: NCT03522870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring system
Description: Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: Performing SMBG at least three times/day on Week 2-14 and Week 14-26
Study: NCT02980224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OmegaD
Description: OmegaD Softgels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Softgels
Study: NCT02941627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Zti
Description: Cochlear implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro One
Description: Sound processor
Study: NCT01262690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05230901
Description: Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05230901
Description: Single dose SC
Study: NCT00337870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAT
Description: Cognitive-Behavioral/Relaxation Intervention
Study: NCT02453204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Study: NCT00758199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Description: Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin hydrochloride
Description: Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone Acetate
Description: Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
Study: NCT04119518

Intervention type: DEVICE
Group type: OTHER
Intervention: CSEM Pulse Watch
Description: Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.
Study: NCT02456363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF alpha
Description: Depending on patient need to use different TNF alpha

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF alpha
Description: Depending on patient need to use different TNF alpha
Study: NCT03104413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab administered as intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab administered as intravenous (IV) infusion.
Study: NCT02237300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR based cue-exposure therapy
Description: Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional Cognitive-behavioral treatment
Description: Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
Study: NCT04153864

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Activation Treatment
Description: A manualized 6-8 session BA treatment delivered individually to each participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment
Description: A manualized 6-8 session BA treatment delivered individually to each participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Activation Treatment
Description: A manualized 6-8 session BA treatment delivered individually to each participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment
Description: A manualized 6-8 session BA treatment delivered individually to each participant.
Study: NCT01197404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Management
Description: 12-session group intervention including affect management training as well as sexual health skills training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 12-session group intervention including health information on a variety of developmentally relevant health topics.
Study: NCT00806559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Re-designed room
Description: In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control room
Description: This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
Study: NCT02982343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Falls management plus exercise training
Description: Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Falls management only
Description: Participants will undergo a session of falls management and education.
Study: NCT01307215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 20mLs of 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 30mLs of 0.33%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 40mLs of 0.25%
Study: NCT01661907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Epi-GA/PCEA
Description: An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.375%-0.5% ropivacaine during surgery. Patient-controlled epidural analgesia will be provided after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GA/PCIA
Description: General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
Study: NCT03620227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
Study: NCT02456363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs and sulfasalazine
Description: randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs and sulfasalazine
Description: randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs and sulfasalazine
Description: randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
Study: NCT01081964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabofloxacin
Description: Zabofloxacin 400mg capsule once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500mg orally for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabofloxacin 400mg
Description: Zabofloxacin 400mg orally for 5 days
Study: NCT03072004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LLLT
Description: That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group
Study: NCT03104413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab IV
Description: risankizumab administered as intravenous (IV) infusion.
Study: NCT03386916

Intervention type: PROCEDURE
Intervention: CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer
Study: NCT01485172

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropinirole monotherapy
Description: ropinirole as monotherapy in Parkinson's disease
Study: NCT03997877

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Increase physical activity Balanced diet
Study: NCT01485172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropinirole monotherapy
Description: ropinirole as monotherapy in Parkinson's disease

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo monotherapy
Description: placebo as monotherapy in Parkinson's disease
Study: NCT03997877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Increase physical activity Balanced diet
Study: NCT02721069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL-1
Study: NCT02549924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, 500 mg 3 times daily with the first bite of each meal
Study: NCT03883841

Intervention type: DRUG
Intervention: Iron Sucrose Solution for Injection
Description: intravenous infusion of iron sucrose
Study: NCT01421355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.
Study: NCT03146299

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLH vs LAVH
Description: TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLH vs LAVH
Description: TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more
Study: NCT04279418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed functional foods supplementation
Description: In this project, taking the method of random, double blindness and control, participants in the mixed functional foods group will take functional foods with main compositions of ginsenoside, green tea polyphenols and marine collagen peptide for three months. After that, neuropsychological tests and neuroimaging biomarkers will be compared between functional food group and placebo group.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this project, taking the method of random, double blindness and control, participants in the placebo group will take placebo for three months. After that, cognitive changes and neuroimaging biomarkers will be compared between functional food group and placebo group.
Study: NCT01034748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PF00299804
Description: Single 45 mg oral dose of radiolabelled PF-00299804
Study: NCT02865707

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synergy-1
Description: Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is carbohydrate adsorbed in the small bowel.
Study: NCT02433080

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shape-Up following cancer treatment
Description: The programme is based on Social Cognitive Theory and Control Theory. The focus of the programme lies on self-control, self-efficacy, and relapse prevention.
Study: NCT03347955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neural implantation group
Description: Cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally for those receiving the implant

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham surgery
Description: Steel frame affixed to head and four burr holes drilled into forehead of sham surgery patients
Study: NCT02803983

Intervention type: PROCEDURE
Intervention: Pediatric hip plate
Description: Children were treated with pediatric hip plate.

Intervention type: PROCEDURE
Intervention: Cannulated screw
Description: Children were treated with cannulated screw.
Study: NCT03373396

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
Study: NCT00885222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS parameters setting
Description: DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS parameters setting
Description: DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS parameters setting
Description: DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
Study: NCT02925884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gunnar OTC Glasses Condition
Description: Gunnar Over-The-Counter Computer Glasses have optical power of 0.5 diopter for reducing accommodation demands at typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
Study: NCT00654433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD-101
Description: A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
Study: NCT04154527

Intervention type: OTHER
Intervention: Pelvic Floor and Abdominal Exercises
Description: two repetitions of each exercise, during exhalation phase

Intervention type: OTHER
Intervention: Pelvic Floor and Abdominal Exercises
Description: two repetitions of each exercise, during exhalation phase
Study: NCT03620227

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
Study: NCT02627261

Intervention type: BIOLOGICAL
Intervention: blood samples and bone marrow aspirates will be collected
Description: Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
Study: NCT02961101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
Study: NCT02015962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous potassium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral potassium chloride
Study: NCT01753648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDOCT
Description: total retinal blood flow (together with DVA), retinal blood velocities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDOCT
Description: total retinal blood flow (together with DVA), retinal blood velocities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocular perfusion pressure
Description: Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ocular perfusion pressure
Description: Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
Study: NCT01367951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical fixation
Description: * The fractures will be reduced and stabilized by use of plates and screws~* Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~* Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~* Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted.
Study: NCT01050517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole + ivermectin + praziquantel
Description: albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albendazole + ivermectin + (1 week later) praziquantel
Description: albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)